Updated efficacy results from Allos Therapeutics' FOLOTYN study to be presented at the ASH meeting

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that abstracts from studies of FOLOTYN (pralatrexate injection) were accepted for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH) to be held at the Ernest N. Morial Convention Center in New Orleans, La., from December 5-8, 2009.

Four poster presentations will summarize new analyses of data and updated efficacy results from the Company’s pivotal PROPEL study, which served as the basis for U.S. Food and Drug Administration’s accelerated approval of FOLOTYN™ on September 24, 2009, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). In addition, there will be a poster summarizing results of a Phase 1 study of FOLOTYN in combination with gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies, and an oral presentation highlighting results of a multicenter, dose-finding study of FOLOTYN in patients with cutaneous T-cell lymphoma (CTCL).

Information regarding the ASH presentations is below and full abstracts can be viewed on the ASH website at www.hematology.org and will be published in the Blood Abstract Book.

Presentation Date/Time: Saturday, December 5, 2009, 5:30-7:30 p.m. (Central)
Poster Title: “Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL)”
First Author: Kerry J. Savage, MD, British Columbia Cancer Agency
Abstract Number: 1678 (Poster Board I-700)
Location: Hall E of the Ernest N. Morial Convention Center

Presentation Date/Time: Saturday, December 5, 2009, 5:30-7:30 p.m. (Central)
Poster Title: “Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)”
First Author: Lauren Pinter-Brown, MD, University of California at Los Angeles
Abstract Number: 1675 (Poster Board I-697)
Location: Hall E of the Ernest N. Morial Convention Center

Presentation Date/Time: Saturday, December 5, 2009, 5:30-7:30 p.m. (Central)
Poster Title: “Correlation between Baseline Methylmalonic Acid Status and Mucositis Severity in the PROPEL Study: Implications for Vitamin Prophylaxis”
First Author: Barbara Pro, MD, University of Texas M.D. Anderson Cancer Center
Abstract Number: 1681 (Poster Board I-703)
Location: Hall E of the Ernest N. Morial Convention Center
Presentation Date/Time: Saturday, December 5, 2009, 5:30-7:30 p.m. (Central)

Poster Title: “Pralatrexate and Gemcitabine in Patients with Relapsed or Refractory Lymphoproliferative Malignancies: Phase 1 Results”
First Author: Steven M. Horwitz, MD, Memorial Sloan-Kettering Cancer Center
Abstract Number: 1674 (Poster Board I-696)
Location: Hall E of the Ernest N. Morial Convention Center
Presentation Date/Time: Monday, December 7, 2009, 6:00-8:00 p.m. (Central)

Poster Title: “Stem Cell Transplant (SCT) and Pralatrexate Therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Who Received SCT Prior to or Following Pralatrexate Therapy”
First Author: Leslie Popplewell, MD, City of Hope
Abstract Number: 3420 (Poster Board III-357)
Location: Hall E of the Ernest N. Morial Convention Center

Oral Presentation Date/Time: Tuesday, December 8, 2009, 7:30 a.m. (Central)
Title: “Pralatrexate is Active in Cutaneous T-Cell Lymphoma (CTCL): Results of a Multicenter, Dose-Finding Trial”
First Author: Steven M. Horwitz, MD, Memorial Sloan-Kettering Cancer Center
Abstract Number: 919
Location: 260-262 Ernest N. Morial Convention Center

Source:

Allos Therapeutics, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Exploring the contribution of COVID-19 prevention network to SARS-CoV-2 vaccine efficacy clinical trials